Latest news with #PreetiFutnani
Mid East Info
09-05-2025
- Health
- Mid East Info
MOU between the Saudi Society of Dermatology and Dermatologic Surgery (SSDDS) and Sanofi - Middle East Business News and Information
Saudi Society of Dermatology and Sanofi Sign MoU to Advance Dermatological Care in Saudi Arabia Riyadh, KSA –May 2025 – The Saudi Society of Dermatology and Dermatologic Surgery (SSDDS), the leading professional organization for dermatologists in Saudi Arabia, has signed a Memorandum of Understanding (MoU) with Sanofi, a global leader in innovative healthcare. This strategic partnership aims to enhance dermatological care in the Kingdom and aligns with the goals of Saudi Vision 2030 to promote innovation and excellence in healthcare. The MoU signifies a collaborative effort to strengthen the role of SSDDS through active partnerships between public and private sectors. The agreement will focus on improving care for chronic and immunological skin diseases—particularly Type 2 inflammatory conditions like atopic dermatitis, which affects up to 20% of children in Saudi Arabia. According to the Ministry of Health, dermatological conditions are among the top reasons for specialist clinic visits, with around 12% of primary healthcare center patients experiencing skin-related issues. Common conditions include atopic dermatitis, psoriasis, acne, and infectious diseases. These disorders often carry a significant psychological and social burden, especially among youth. The rise in allergic skin conditions due to environmental and climatic factors further highlights the need for heightened awareness and innovative treatment approaches. The MoU signing ceremony was attended by key stakeholders from the healthcare sector and Sanofi representatives. Dr. Abdullah Al-Akeel, President of SSDDS, commented: 'We are excited to launch this partnership with Sanofi. This collaboration will support medical education, promote scientific research, and enhance clinical practices across the Kingdom. It will empower Saudi dermatologists to remain at the forefront of global advancements and deliver optimal care to their patients.' Preeti Futnani, MCO Lead and Specialty Care General Manager for Greater Gulf at Sanofi, added: 'At Sanofi, we believe that strong partnerships with national scientific bodies are key to sustainable innovation. Through our collaboration with SSDDS, we aim to expand access to advanced treatments and strengthen patient support programs such as 'My Journey with Dupilumab,' ultimately improving patient outcomes and experiences.' As part of the partnership, SSDDS and Sanofi will jointly launch certified training programs, organize scientific conferences, and conduct specialized workshops. The initiative also includes public awareness campaigns and a focus on digital transformation to improve diagnostic capabilities and healthcare service delivery. This landmark agreement underscores the shared commitment of SSDDS and Sanofi to improving dermatological health and building a more resilient, innovative healthcare ecosystem in Saudi Arabia.
Zawya
19-02-2025
- Health
- Zawya
Saudi Arabia inaugurates first local insulin manufacturing facility, advancing healthcare self-sufficiency
In a landmark moment for Saudi Arabia's healthcare sector, the Kingdom inaugurated its first local insulin manufacturing facility, a key milestone in advancing pharmaceutical self-sufficiency under Vision 2030. The state-of-the-art facility, established through a collaboration between Sanofi, Sudair Pharma Company (SPC), and NUPCO, aims to enhance national drug security and improve access to life-saving insulin for millions of patients living with diabetes. The inauguration ceremony was attended by Bandar Al-Khorayef, Minister of Industry and Mineral Resources, alongside senior government officials, healthcare leaders, and industry partners. With diabetes affecting nearly 19% of Saudi Arabia's adult population, ensuring a stable and reliable supply of insulin has been a national priority. Historically reliant on imports, the Kingdom is now taking a transformative step toward localizing production to reduce supply chain vulnerabilities and provide more accessible treatment options. Preeti Futnani, MCO Lead and Specialty Care General Manager for Greater Gulf at Sanofi, underscored the company's long-standing commitment to Saudi Arabia and its role in supporting the nation's health transformation. 'Sanofi's journey in Saudi Arabia has always been about building something meaningful, and today, we take a major step forward,' Futnani stated. 'With this insulin manufacturing facility, we are not just producing medicine—we are investing in the country's future by ensuring a reliable supply of high-quality insulin, reducing dependency on imports, and empowering local talent to sustain this progress.' Once fully operational, the facility is expected to produce approximately 15 million insulin pens annually, covering the needs of 500,000 patients across Saudi Arabia. This production milestone will provide 70% of the insulin required by diabetic patients in the Kingdom, significantly enhancing national pharmaceutical security. Dr. Yasser AlObaida, Chief Executive Officer of Sudair Pharma Company, said: "At Sudir Pharma, we are pleased to collaborate with NUPCO and Sanofi in the establishment of this integrated facility. It will manufacture three types of insulin, including the latest biological insulin, which is widely used in diabetes treatment. The facility relies on the latest technologies throughout its manufacturing and packaging stages. The success of this initiative is driven by the unwavering support offered by all relevant authorities, including the Ministry of Health, the Ministry of Industry, and others, as well as the favorable policies and regulations in Saudi Arabia.' Beyond production, the facility is designed to support the Kingdom's ambition to develop a sustainable healthcare ecosystem by equipping local talent with specialized skills. This focus aligns with the broader objectives of the Health Sector Transformation Program, a key pillar of Vision 2030 aimed at improving healthcare accessibility and advancing medical innovation. Sanofi, a global healthcare leader, has been present in Saudi Arabia for more than 50 years and has continuously invested in initiatives that support the country's healthcare goals. The localization of insulin production reflects the company's deep-rooted partnership with the Kingdom and its dedication to strongly contribute to Saudi Vision 2030. 'As our CEO Paul Hudson said during his participation in FII8 last year, 'The sky is the limit for future collaborations in the Kingdom for Sanofi,'' Futnani remarked. 'While today is a milestone, it is just the beginning. We are committed to working alongside Saudi Arabia in shaping the future of healthcare and leaving a lasting impact for generations to come.' The inauguration of the facility marks a pivotal step in Saudi Arabia's healthcare transformation, ensuring that patients have access to world-class treatment produced in Saudi, for Saudi, by Saudi. © Copyright 2022 The Saudi Gazette. All Rights Reserved. Provided by SyndiGate Media Inc. (
